Multiple gene therapy as a tool for regulating the expression of molecules involved in neovascular age-related macular degeneration

黄斑变性 遗传增强 PEDF公司 血管内皮生长因子 医学 血管抑制剂 视网膜 阿柏西普 生物信息学 视网膜色素上皮 视网膜 眼科 神经科学 癌症研究 生物 内科学 基因 血管内皮生长因子受体 贝伐单抗 化疗 遗传学
作者
Thomas J. Corydon,Toke Bek
出处
期刊:Progress in Retinal and Eye Research [Elsevier BV]
卷期号:: 101323-101323
标识
DOI:10.1016/j.preteyeres.2024.101323
摘要

Anti-vascular endothelial growth factor (VEGF) therapies have revolutionized the treatment of neovascular age-related macular degeneration (nAMD) and other retinal diseases. However, the necessity for repeated intravitreal injections and the observation of variable treatment responses calls for new treatment modalities where fewer and more effective interventions can result in a clinical effect. Gene therapy might be such an alternative, and therefore the development and clinical application of gene therapy aimed at modifying gene expression has received considerable attention. The article reviews current knowledge of the background, pathophysiological mechanisms, technologies, limitations, and future directions for gene therapy aimed at modifying the synthesis of compounds involved in acquired and senescent retinal disease. The authors have contributed to the field by developing gene therapy to reduce the expression of vascular endothelial growth factor (VEGF), as well as multiple gene therapy for simultaneous downregulation of the synthesis of VEGF and upregulation of pigment epithelium-derived factor (PEDF) using adeno-associated virus (AAV) vectors. It is suggested that such multi-target gene therapy might be included in future treatments of retinal diseases where the underlying mechanisms are complex and cannot be attributed to one specific mediator. Such diseases might include dry AMD (dAMD) with geographic atrophy, but also diabetic macular edema (DME) and retinal vein occlusion (RVO). Gene therapy can be expected to be most beneficial for the patients in need of multiple intra-vitreal injections and in whom the therapeutic response is insufficient. It is concluded, that in parallel with basic research, there is a need for clinical studies aimed at identifying factors that can be used to identify patients who will benefit from gene therapy already at the time of diagnosis of the retinal disease.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
hzr发布了新的文献求助10
刚刚
快乐太英完成签到,获得积分10
1秒前
1秒前
科研通AI5应助开心的瘦子采纳,获得10
2秒前
2秒前
GYGeorge发布了新的文献求助20
3秒前
千堆雪发布了新的文献求助10
4秒前
偑厸发布了新的文献求助10
5秒前
天天发布了新的文献求助10
5秒前
FashionBoy应助东方一斩采纳,获得10
7秒前
7秒前
XuanWayne完成签到,获得积分10
7秒前
暴躁的电话完成签到,获得积分10
7秒前
7秒前
可耐的凌旋完成签到 ,获得积分10
8秒前
8秒前
CJY发布了新的文献求助10
8秒前
Akim应助JMchiefEditor采纳,获得10
9秒前
吱布吱布发布了新的文献求助10
11秒前
Laus发布了新的文献求助10
13秒前
14秒前
槿裡完成签到 ,获得积分10
14秒前
戏影感关注了科研通微信公众号
15秒前
张先生发布了新的文献求助10
15秒前
16秒前
赵靖易发布了新的文献求助30
20秒前
LanceHayward完成签到,获得积分10
20秒前
桐晚晚晚发布了新的文献求助10
21秒前
21秒前
科研通AI5应助Laus采纳,获得10
22秒前
23秒前
24秒前
CJY完成签到,获得积分10
25秒前
小马甲应助可耐的凌旋采纳,获得10
25秒前
wewe完成签到,获得积分10
26秒前
zho发布了新的文献求助10
26秒前
友好的妙松完成签到,获得积分10
26秒前
26秒前
哎咦随风起完成签到,获得积分10
27秒前
28秒前
高分求助中
【此为提示信息,请勿应助】请按要求发布求助,避免被关 20000
Continuum Thermodynamics and Material Modelling 2000
ISCN 2024 – An International System for Human Cytogenomic Nomenclature (2024) 1000
CRC Handbook of Chemistry and Physics 104th edition 1000
Izeltabart tapatansine - AdisInsight 600
Maneuvering of a Damaged Navy Combatant 500
An International System for Human Cytogenomic Nomenclature (2024) 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3769645
求助须知:如何正确求助?哪些是违规求助? 3314713
关于积分的说明 10173349
捐赠科研通 3030002
什么是DOI,文献DOI怎么找? 1662548
邀请新用户注册赠送积分活动 795036
科研通“疑难数据库(出版商)”最低求助积分说明 756500